miR-29在胃癌中的表达及其临床意义

Expression of miR-29 in gastric cancer and its clinicopathological significance

目的观察胃癌组织中miR-29的表达情况及其与年龄、性别、分化程度、淋巴结转移、TNM分期和预后的关系,探讨miR-29在胃癌中表达的临床意义及其价值。方法收集胃癌手术标本,采用Trizol试剂抽提总RNA,采用实时荧光定量PCR技术检测86例胃癌组织中miR-29的表达水平,并对所有病例进行随访。结果有淋巴结转移的胃癌患者miR-29低表达的比例显著高于无淋巴结转移组(59.6%vs.25.0%,P=0.004),Ⅰ、Ⅱ期胃癌患者miR-29低表达的比例显著高于Ⅲ、Ⅳ期患者(63.8%vs.40.0%,P=0.029),miR-29与年龄、性别、分化程度无关。43例miR-29低表达胃癌患者的中位生存期为35.0月,3年生存率为39.6%;43例高表达者的中位生存期为44.0月,3年生存率为66.1%,两组差异显著(P=0.007)。结论 miR-29在胃癌组织中高表达能抑制肿瘤淋巴结转移进而改善预后,可作为胃癌的预后判断指标及治疗靶标。

Objective To explore the expression of miR-29 in gastric cancer and its relationship with clinical pathological features and prognosis.Methods The expression of miR-29 in 86 cases of gastric cancer was tested by real time PCR.Results The rate of low miR-29 expression in cases of lymph node metastases was significantly higher than those without lymph node metastases（59.6% vs.25.0%,P=0.004）.The rate of low miR-29 expression in cases of TNM stage Ⅰ/Ⅱ was significantly higher than those of TNM stage Ⅲ/Ⅳ（63.8% vs.40.0%,P=0.029）.The median overall survival in low miR-29 expression cases was significantly lower than that in high miR-29 expression cases（35.0 months vs.44.0 months,P=0.007）.And the 3 year accumulative survival rate in low miR-29 expression cases was also significantly lower than that in high miR-29 expression cases（39.6% vs.66.1%,P=0.007）.Conclusion The higher expression of miR-29 in gastric cancer can suppress tumor metastasis,and also improves prognosis.miR-29 could not only act as a predictor of prognosis,but also as a theraputic target of gastric cancer.